一种新型抗肿瘤药物1,4 - 二羟基 - 5,8 - 双[[2 - [(2 - 羟乙基)氨基] - 乙基]氨基] - 9,10 - 蒽二酮与核酸的相互作用。 - Suppr

Suppr

超能文献

Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.

作者信息

Kapuscinski J, Darzynkiewicz Z, Traganos F, Melamed M R

出版信息

Biochem Pharmacol. 1981 Feb 1;30(3):231-40. doi: 10.1016/0006-2952(81)90083-6.

DOI:10.1016/0006-2952(81)90083-6

PMID:7225141

Abstract

摘要

相似文献

Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.一种新型抗肿瘤药物1,4 - 二羟基 - 5,8 - 双[[2 - [(2 - 羟乙基)氨基] - 乙基]氨基] - 9,10 - 蒽二酮与核酸的相互作用。

Biochem Pharmacol. 1981 Feb 1;30(3):231-40. doi: 10.1016/0006-2952(81)90083-6.

Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis.通过共聚焦光谱成像分析探究米托蒽醌在活K562细胞内的定位及分子相互作用。

Biophys J. 1997 Dec;73(6):3317-27. doi: 10.1016/S0006-3495(97)78356-5.

Effects of 9,10-anthracenedione, 1,4-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-, diacetate on cell morphology and nucleic acids of friend leukemia cells.9,10-蒽二酮-1,4-双[[2-[(2-羟乙基)氨基]乙基]氨基]二乙酸酯对弗瑞德白血病细胞的细胞形态和核酸的影响

J Natl Cancer Inst. 1980 Apr;64(4):857-66.

Competitive fluorescence polarization study of the binding of 1,4-dihydroxy-5,8-bis[(2-[(2-hydroxyethyl) amino] ethyl]amino] 9-10-anthracenedione to DNA.

Res Commun Chem Pathol Pharmacol. 1980 Mar;27(3):497-506.

Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione.1,4 - 二羟基 - 5,8 - 双[（2 - [（2 - 羟乙基）氨基]乙基]氨基] - 9,10 - 蒽二酮的临床动力学

Clin Pharmacol Ther. 1982 Mar;31(3):312-6. doi: 10.1038/clpt.1982.39.

An antineoplastic C14-labeled methylhydrazine derivative in P815 mouse leukemia. A metabolic study.一种用于P815小鼠白血病的C14标记甲基肼衍生物的抗肿瘤药。一项代谢研究。

Experientia. 1965 May 15;21(5):284-6. doi: 10.1007/BF02297032.

Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.蒽环类抗癌药物米托蒽醌和比生群在白血病L1210细胞中的比较分子药理学

Cancer Res. 1985 Oct;45(10):4915-20.

[Mitoxantrone HCl (1,4-dihydroxy-4, 8-bis[[2-(hydroxyethyl)-amino-ethyl)]amino 9,10-anthracenedione dihydrochloride (NSC 301739) - a new cytostatic].盐酸米托蒽醌（1,4 - 二羟基 - 4,8 - 双[[2 - （羟乙基） - 氨基 - 乙基]]氨基 - 9,10 - 蒽二酮二盐酸盐（NSC 301739）——一种新型细胞抑制剂。

Onkologie. 1980 Dec;3(6):322-8. doi: 10.1159/000214816.

Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.新型蒽二酮1,4 - 二羟基 - 5,8 - 双（（（2 - [（2 - 羟乙基）氨基]乙基）氨基）） - 9,10 - 蒽二酮二盐酸盐（NSC 301739）的I期临床研究

Cancer Res. 1980 May;40(5):1516-8.

Structure-activity relationship study of anthraquinones: 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethoxy)ethyl]amino]-9,10-anthracenedione, an analog of an established antineoplastic agent.蒽醌类化合物的构效关系研究：1,4 - 二羟基 - 5,8 - 双[[2 - (2 - 羟基乙氧基)乙基]氨基] - 9,10 - 蒽二酮，一种已确立的抗肿瘤药物的类似物。

J Pharm Sci. 1982 Jun;71(6):708-9. doi: 10.1002/jps.2600710626.

引用本文的文献

Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers.利用磁镊技术研究抗癌化疗药物米托蒽醌与 DNA 的结合机制。

J Nanobiotechnology. 2018 Jul 13;16(1):56. doi: 10.1186/s12951-018-0381-y.

A novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formation.一种新型高通量生化测定法，用于评估 HuR 蛋白-RNA 复合物的形成。

PLoS One. 2013 Aug 12;8(8):e72426. doi: 10.1371/journal.pone.0072426. eCollection 2013.

Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes.磁性药物靶向治疗可减轻循环白细胞的化疗负担。

Int J Mol Sci. 2013 Apr 2;14(4):7341-55. doi: 10.3390/ijms14047341.

DNA damage signaling assessed in individual cells in relation to the cell cycle phase and induction of apoptosis.在细胞周期阶段和凋亡诱导方面，评估个体细胞中的 DNA 损伤信号。

Crit Rev Clin Lab Sci. 2012 Sep-Dec;49(5-6):199-217. doi: 10.3109/10408363.2012.738808. Epub 2012 Nov 9.

Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.米托蒽醌在活K562细胞内的定量共聚焦光谱成像分析：单体、聚集体、萘并喹喔啉代谢物及药物-靶点复合物的细胞内积累与分布

Biophys J. 1997 Dec;73(6):3328-36. doi: 10.1016/S0006-3495(97)78357-7.

Biophys J. 1997 Dec;73(6):3317-27. doi: 10.1016/S0006-3495(97)78356-5.

Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation.细胞增殖抑制剂对诺维科夫肝癌细胞中DNA聚合酶α、δ和ε的选择性抑制作用

J Cancer Res Clin Oncol. 1996;122(2):78-94. doi: 10.1007/BF01226265.

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.将细胞毒性蒽醌类脂肪族氮氧化物用作前药DNA结合剂的原理：一类新型生物还原剂。

Cancer Metastasis Rev. 1993 Jun;12(2):119-34. doi: 10.1007/BF00689805.

DNA sequence specificity of mitoxantrone.米托蒽醌的DNA序列特异性。

Nucleic Acids Res. 1994 Apr 25;22(8):1342-5. doi: 10.1093/nar/22.8.1342.

Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells.抗肿瘤药物米托蒽醌的亚细胞定位以及耐药和敏感人结肠癌细胞中DNA损伤的诱导

Cancer Chemother Pharmacol. 1995;35(5):403-10. doi: 10.1007/s002800050254.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验